Best Practices for Successful Sell-Side Licensing, Partnering and M&A

Best Practices for Successful Sell-Side Licensing, Partnering and M&A
with Stephan Gauldie, PhD, Gregory Benning and Jonathan P. Gertler, MD, Back Bay Life Science Advisors and BioVentures MedTech Funds

Show Notes

Despite the heavy influx of capital over the past years, medtech or biopharma sell-side assignments can still be ripe with challenges. In this episode of Back Bay’s industry podcast, Back Bay Life Science Advisors’ investment banking team discuss best practices for successful sell-side licensing, partnering, and M&A, including: 

• Best practices for readying vital aspects of deal preparation 
• Identifying deal issues, red flags ahead of time
• Articulation of the path forward, including indication and proof of concept and telling the story through to market
• The importance of choosing the right partner and alignment for stakeholders, management, board, investors, internal champions and others
• The most significant mistakes made in competitive intelligence, technology, position, IP regulatory strategies
• Networking, contacts and how to know who’s going to be responsible for what and when

Make sure to subscribe to The Life Science Report podcast and follow Back Bay Life Science Advisors on LinkedIn. Thank you for joining us.

What is Back Bay Life Science Report?

Back Bay Life Science Advisors brings you expert insights from our advisors and investment bankers in the world of BioPharma & MedTech. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech executives, physicians, and strategists who excel at guiding global life sciences companies and their investors through complex decisions. Join us for insights generated from in-depth scientific, strategic, and financial analysis at the intersection of science and business.